Literature DB >> 11830288

Protein distribution of the orexin-2 receptor in the rat central nervous system.

J E Cluderay1, D C Harrison, G J Hervieu.   

Abstract

Orexin-A and -B are neuropeptides mainly expressed in the lateral hypothalamic area (LHA). A role for orexins was first demonstrated in the regulation of feeding behaviour. Subsequently, the peptides have been implicated in the control of arousal. To date, two receptors for orexins have been characterised: orexin-1 and -2 receptors (OX-R1 and OX-R2). Both receptor genes are widely expressed within the rat brain. Particularly high expression of both receptor genes in certain hypothalamic and pons nuclei could be responsible for the orexigenic and arousal properties of the peptides. It is, however, presently unclear if one given receptor subtype or both subtypes may mediate a specific biological effect of orexins such as an increase in food intake. We have recently reported the distribution of the OX-R1 protein in the rat nervous system. In this study, we report the distribution of the OX-R2 protein in the rat brain and spinal cord using specific anti-peptide antisera raised against the OX-R2 protein. We also assess the expression profile of the OX-R2 gene in different brain regions. Immunolabelling for the OX-R2 protein was observed in brain regions that exhibited OX-R1-like immunoreactivity (cerebral neocortex, basal ganglia, hippocampal formation, and many other regions in the hypothalamus, thalamus, midbrain and reticular formation). Differences in the OX-R1 and OX-R2 distribution were, however, noticed in the hippocampus, hypothalamus and dorso-lateral pons.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11830288     DOI: 10.1016/s0167-0115(01)00357-3

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  71 in total

1.  Orexin A in rat rostral ventrolateral medulla is pressor, sympatho-excitatory, increases barosensitivity and attenuates the somato-sympathetic reflex.

Authors:  Israt Z Shahid; Ahmed A Rahman; Paul M Pilowsky
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  Hypocretin/orexin involvement in reward and reinforcement.

Authors:  Rodrigo A España
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

Review 3.  Energy expenditure: role of orexin.

Authors:  Jennifer A Teske; Vijayakumar Mavanji
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

4.  Lateral Hypothalamic Stimulation Reduces Hyperalgesia Through Spinally Descending Orexin-A Neurons in Neuropathic Pain.

Authors:  Jacob Wardach; Monica Wagner; Younhee Jeong; Janean E Holden
Journal:  West J Nurs Res       Date:  2015-10-15       Impact factor: 1.967

5.  Upregulation of orexin receptor in paraventricular nucleus promotes sympathetic outflow in obese Zucker rats.

Authors:  Jing-Jing Zhou; Fang Yuan; Yi Zhang; De-Pei Li
Journal:  Neuropharmacology       Date:  2015-08-12       Impact factor: 5.250

6.  The brain orexin system and almorexant in fear-conditioned startle reactions in the rat.

Authors:  Michel A Steiner; Hugues Lecourt; Francois Jenck
Journal:  Psychopharmacology (Berl)       Date:  2012-05-17       Impact factor: 4.530

7.  Orexin/hypocretin-1 receptor antagonism reduces ethanol self-administration and reinstatement selectively in highly-motivated rats.

Authors:  David E Moorman; Morgan H James; Elisabeth A Kilroy; Gary Aston-Jones
Journal:  Brain Res       Date:  2016-10-19       Impact factor: 3.252

8.  Orexin receptor subtype activation and locomotor behaviour in the rat.

Authors:  W K Samson; S L Bagley; A V Ferguson; M M White
Journal:  Acta Physiol (Oxf)       Date:  2009-11-04       Impact factor: 6.311

Review 9.  Implicating the potential role of orexin in hypertension.

Authors:  Monika Rani; Raghuvansh Kumar; Pawan Krishan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-05-16       Impact factor: 3.000

10.  Centrally administered orexin A increases motivation for sweet pellets in rats.

Authors:  A J Thorpe; J P Cleary; A S Levine; C M Kotz
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.